Hi Rupesh,
Rgdg. your queries……
(1) Since Syngene has only recently came out with its IPO so risk factors are very well documented in RHP — you can refer that.
If you ask me then the biggest risk factor is not meeting the delivery schedules of customers is the biggest risk factor to me. NMEs are very sensitive contracts where if you falter on even one thing then customer suffers alot — even more than you –so margin of error is minimal in such contracts. This ofcourse I am talking about commercial manufacturing……having said these, it is because of this factor that inspections and checks are most stringent while catering to this segment and unless customer is working with you since last many years (in many cases decade) and is fully satisfied of your capability and integrity that he will enter into contract with you.
Second biggest risk factor is any mismanagement during CAPEX i.e., any delay or something, especially Mangalore plant once work starts there next year.
(2) Name of the molecules as well as many customers might not be talked in detail because of NDAs signed by the company because of confidentiality issues involved in the sector. If you have researched PIIND before then you must very well know this.
As far as what company is actually doing, as said before, RHP is filed only before two months and there is no point in discussing entire thing again here. Still from RHP if you don’t understand anything then here that can be explained lucidly.
Feel free to get back in case of any further query.
Rgds.
| Subscribe To Our Free Newsletter |
